Cubała WJ
Division of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
ArticleLSD
DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder.
ArticleKetamine
Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients.
ArticleDMT
Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis.
ArticleKetamine
Short-term ketamine interventions for depressive disorders: practical best-practice recommendations for psychiatrists using oral, subcutaneous, and nasal formulations.
ArticleKetamine
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].
ArticleKetamine
Appetite measures during ketamine administration in treatment-resistant mood disorders: a naturalistic study.
ArticlePsilocybin
Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.
ArticleKetamine
Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.
ArticleKetamine
Patient-centred education for ketamine and esketamine therapies in mood disorders.
ArticleKetamine
Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.
ArticlePsychedelics
Variability in AI-generated psychedelic definitions across major chatbots.
ArticleKetamine
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
ArticleDMT
GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial.
ArticleKetamine
Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis.
ArticlePsychedelics
Regulatory context for protocol amendments and public reporting in psychedelic trials.
ArticleKetamine
Clinical correlates of anhedonia non-response to ketamine in treatment-resistant depression.
ArticlePsychedelics
Public attitudes toward psychedelics in Poland: a constructive commentary on Holas & Kamińska (2025).
ArticleKetamine
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.
ArticleKetamine
Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity.
ArticleKetamine
Oxidative Stress in Treatment-Resistant and Refractory Depression: A Hidden Therapeutic Target?
ArticleKetamine
Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.
ArticlePsilocybin
Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols.
ArticleKetamine
Patients' Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives.
ArticleKetamine
Ketamine in post-stroke depression: a report of 2 cases.
ArticleKetamine
Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression.
ArticleKetamine
Appetite measures as correlates of clinical response in mood disorders treated with ketamine: systematic review.
ArticleKetamine
The Effect of Ketamine on the Immune System in Patients with Treatment-Resistant Depression.
ArticlePsilocybin
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.
ArticleDMT
Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.
ArticleKetamine
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.
ArticlePsilocybin
Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis.
ArticleIbogaine
Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.
ArticlePsilocybin
Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis.
ArticleKetamine
The Need for Guidance on Ketamine/Esketamine Use in Real-World Clinical Settings.
ArticleKetamine
Comment on "Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis".
ArticlePsilocybin
Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.
ArticleDMT
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.
ArticleKetamine
Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.
ArticleKetamine
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review.
ArticleKetamine
Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration.
ArticleKetamine
Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression.
ArticleKetamine
Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management.
ArticleKetamine